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Abstract
Background: Medication related harm (MRH) is a common cause of morbidity and hospital admission in the
elderly, and has significant cost implications for both primary and secondary healthcare resources. The
development of risk prediction models has become an increasingly common phenomenon in medicine and can be
useful to guide objective clinical decision making, resource allocation and intervention. There are no risk prediction
models that are widely used in clinical practice to identify elderly patients at high risk of MRH following hospital
discharge. The aim of this study is to develop a risk prediction model (RPM) to identify elderly patients at high risk
of MRH upon discharge from hospital, and to compare this with routine clinical judgment.
Methods/Design: This is a multi-centre, prospective observational study following a cohort of patients for 8 weeks
after hospital discharge. Data collection including patient characteristics, medication use, social factors and frailty
will take place prior to patient discharge and then the patient will be followed up in the community over the next
8 weeks to determine if they have experienced MRH. Research pharmacists will determine whether patients have
experienced MRH by prospectively reviewing records for unplanned emergency department attendance, hospital
readmission and GP consultation related to MRH. Research pharmacists will also telephone patients directly to
determine self-reported MRH, which patients may not have sought further medical attention for. The data collected
will inform the development of a RPM which will be externally validated in a follow-up study.
Discussion: There are no RPMs that are used in clinical practice to help stratify elderly patients at high risk of MRH
in the community following hospital discharge, despite this being a significant public health problem. This study
plans to develop a clinically useful RPM that is better than routine clinical judgment. As this is a multi-centre study
involving clinical settings that serve elderly people of heterogeneous sociodemographic background, it is
anticipated that this RPM will be generalizable.
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Background
Medication related harm (MRH) in older people is a sig-
nificant cause of increased morbidity, hospitalisation,
longer hospital stay and increased healthcare costs [1].
In people aged 65 years or older, hospital admissions at-
tributable to medication related problems range between
5.3 to 30.7 % [1]. Adverse Drug Reactions (ADR) is a
subset of medication related harm. A large prospective
UK study of 18,820 patients reported a prevalence of
hospital admission secondary to ADR of 6.5 %, of which
almost three-quarters (72 %) were potentially avoidable
[2]. Although this study considered all patients aged over
16, the average age of patients admitted with ADR was
76 years old. A more recent UK study of a hospitalized
population of very elderly patients (over 80 years of age)
reported an inpatient ADR incidence of 13.2 %, with
63 % considered preventable [3]. The annual cost to the
NHS of admissions secondary to ADR in the UK was es-
timated at £466 million [2].
A study in the Netherlands of 106 medical inpatients
aged 70 and over found a prevalence of severe ADR of
24 and 12 % of these elderly patients were admitted due
to ADR [4].
A large, retrospective US study found that almost
100,000 elderly patients required emergency hospita-
lization as a direct result of ADR each year, with nearly
half occurring in those over the age of 80 years [5]. A
meta-analysis highlighted that the elderly were four
times more likely to be admitted to hospital as a result
of an ADR when compared to younger patients (16.6 %
compared to 4.1 %), highlighting the increased vulner-
ability of an older population [6]. This increased vulner-
ability of the elderly population is multifactorial and
includes polypharmacy, co-morbidities, renal and hep-
atic impairment and changes in pharmacokinetics and
pharmacodynamics, cognitive impairment and altered
adherence [7].
Risk prediction models (RPM) are increasingly used
within healthcare to personalize and target clinical inter-
ventions. Four RPMs have been developed to date to
predict ADR in older adults, although none are in
current clinical use [8–11]. These models allocate scores
to specific clinical parameters to identify patients at high
risk of ADR during hospital admission. These four
models showed at best a moderate predictive ability
(Area under the receiver operator curve 0.623 to 0.73),
and have not demonstrated an improvement in routine
care. Three of these studies were based on prospective
cohort data [9–11], whilst Onder et al’s (2010) Geront-
oNet ADR risk score was based on retrospective data.
McElnay et al. [10] developed the first tool based on
data collected from inpatients at one UK hospital. This
study identified several important risk factors for adverse
drug events but the model developed had low sensitivity
and specificity (40.5 and 69 % respectively). Trivalle
et al. [11] developed a risk prediction model based on
data collected from several rehabilitation hospital units in
Paris, France, that was entirely based on medications as
risk variables (number of medications, use of anticoagu-
lant, use of neuroleptic). The other two ADR risk predic-
tion models were based on data collected from a multi-
centre European study (GerontoNet) and a study at one
large teaching hospital in the UK (Brighton Adverse Drug
Reactions Risk Model; BADRI). Both of these models
(GerontoNet and BADRI) were developed to identify
patients at risk of ADR whilst in hospital, and neither con-
sidered social measures as potential risk variables.
Given that at least one-fifth of hospital readmissions
of elderly people in the UK are secondary to ADR [12],
it is of both ethical and economic importance that
elderly patients at high risk of MRH following hospital
discharge are identified through objective and evidence
based means. Following this process, appropriate mecha-
nisms to reduce the risk of MRH can be initiated. The
PRIME study intends to bridge this gap in prognostic re-
search by developing a RPM to identify elderly patients
at high risk of MRH at the point of hospital discharge.
To our knowledge such a study has not been previously
conducted. Prognostic research has thus far lacked
transparency and this protocol paper is a step to ad-
dressing this issue [13]. If this RPM demonstrates a high
prognostic value then it could be incorporated into local
care pathways to minimize the occurrence of post-
discharge MRH among elderly people. This proposal
follows Medical Research Council (MRC) guidance relat-
ing to ‘Developing & Evaluating Complex Interventions’
which specifies the need for developmental work prior
to a full evaluation [14].
Study hypothesis
The use of a risk prediction model (RPM) to identify
patients at risk of experiencing MRH will better
predict these events compared to routine clinical
judgment.
Primary objective
To develop a RPM to identify elderly patients at risk of
MRH in the 8 week period following hospital discharge.
Secondary objectives
1. To compare the predictive power of the RPM to
intuitive decisions (i.e. standard care) in relation to
actual MRH experienced in the 8 week period
following hospital discharge.
2. To determine the frequency of health care
utilization secondary to MRH in the 8 week period
following hospital discharge.
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3. To describe the medications commonly causing
MRH, the type of events occurring, their severity
and preventability.
4. To describe local factors, such as ethnicity and
complexity of health care systems, which impact on
MRH frequency, type and severity.
Methods/Design
The PRIME study is a prospective observational study
that aims to develop a risk prediction model (RPM) that
(1) can identify elderly patients at high risk of MRH
upon discharge from hospital and (2) is superior to rou-
tine clinical judgment.
The PRIME study protocol was approved by the Na-
tional Research Ethics Service, East of England (Norfolk;
REC Reference 13/EE/0075), and was funded by the
National Institute of Health Research (NIHR)- Research
for Patient Benefit (RfPB) (PB-PG-0711-25094) and
adopted as a Clinical Research Network portfolio study
(Ageing and Primary Care).
Stage I of the study will involve a critical review of the
medication RPMs in published literature, as they relate to
elderly people, to inform the data collection for Stage II.
Stage II will comprise the development of a new RPM
by using a prospective, observational study design to fol-
low a cohort of 1500 elderly patients for 8 weeks after
discharge from an acute care setting into the community.
Patients will be invited to participate in this study during
their inpatient stay and consent (or assent) obtained as
close to discharge as possible. The study will collect a
range of baseline clinical, medication and social data by
trained research nurses that will be potential pre-
dictor variables to inform the RPM (Please see Fig. 1
and Additional file 1: Table S2). In addition, the views
of the discharging medical team on the likelihood of
the patient experiencing MRH will be recorded. Dur-
ing the 8 week follow-up MRH will be determined by
a research pharmacist through patient/carer self-report via
telephone interview, review of primary care records and
assessment of any re-admissions to the recruiting hospital.
Along with using statistical methods to identify pre-
dictor variables from the data collected to develop the
risk prediction model, an expert panel will be established
to identify important predictor variables for inclusion in
the model development.
Setting
This study will be led by the Academic Department of
Geriatrics (Brighton & Sussex University Hospitals NHS
Trust) in collaboration with the Department of Ageing
and Health (Guy’s & St Thomas’ NHS Foundation Trust).
The study will be undertaken in acute elderly care in-
patient wards at 5 NHS hospitals in the UK. Access to pa-
tient primary care information, during the 8-week follow
up period, will be facilitated through the UK Primary Care
Research Network.
Population
Patients aged 65 years and over who are judged clinically
fit for discharge from the acute Care of the Elderly and
General Medicine wards will be eligible to participate.
Written consent will be obtained from all participants.
Where a patient lacks capacity to consent, their next of
kin will be asked to act as a personal consultee and to
support their relative taking part in the study. It is im-
portant to include those who lack capacity, as we do not
wish to exclude those who are most likely to experience
MRH i.e. those most vulnerable due to frailty and/or
cognitive limitation. If a potential participant lacks cap-
acity and the next of kin is not available, they will not be
included in the study. Patients who consent to be in-
cluded in the study will be allocated a Unique Patient
Identifier Number (UPIN).
Inclusion criteria
Patients must be over the age of 65 years at the time of
recruitment and registered with a General Practitioner
within the areas covered by the recruiting hospitals.
Exclusion criteria
 Patients who lack capacity and have no nominated
consultee,
 Patients that are transferred to other acute
healthcare trusts (but excluding step down or
intermediate care facilities),
 Patients who have a short life expectancy, due to a
terminal illness
Definitions
Medication related harm (MRH) for this study will in-
clude adverse drug reactions and a failure to receive
medication, either following non-adherence or a failure
in the supply chain. This definition is a modified version
of the Strand (1990) definition of a drug-related problem
(DRP) ‘A DRP exists when a patient experiences or is
likely to experience either a disease or symptom having
an actual or suspected relationship with drug therapy’
[15]. This definition was agreed by a panel of experts
(2 Professors of geriatric medicine, UK and Netherlands; 2
consultant geriatricians, UK; Professor of clinical phar-
macy and therapeutics, UK; 2 clinical pharmacists specia-
lising in geriatrics, UK).
Baseline data collection
Baseline data will be collected by trained research nurses
including demographic (e.g. age, gender, ethnicity), clin-
ical (e.g. discharge diagnosis, co-morbidities, renal and
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hepatic function) and social indicators (e.g. care package
received and living arrangements) using a form specific-
ally designed to allow the data to be scanned into an
electronic database for future analysis. Information relat-
ing to medication name, frequency, dose and use of
compliance aids will be collected and coded according
to the WHO-ATC code (http://www.whocc.no/atc_ddd_
index/). In addition validated tools will be used to collect
information relating to nutritional status (Malnutrition
Universal Screening Tool), physical function (Barthel
Activities of Daily Living Index, Hand Grip strength), cog-
nitive function (Abbreviated Mental Test Score) and de-
pression and anxiety (Patient Health Questionnaire-2,
Generalised Anxiety Disorder scale-2). Some of these tool
are routinely measured in elderly care wards in the UK
and if this was not the case the research nurse would ob-
tain the measurement. The hand grip strength of partici-
pants will be measured using the method described in the
Southampton Protocol for Adult Grip strength Measure-
ment using the JAMAR Hydraulic Hand Dynamometer
[16]. The MUST score is routinely used on elderly care
wards and is a five-step screening tool to identify adults,
who are malnourished, at risk of malnutrition (under-
nutrition) or obese [17]. The Barthel ADL Index is a
validated scale used to measure performance in activities
in daily living (ADL) [18].
Data will be collected directly from the hospital re-
cords, following discussion with members of the care
team and with patients and/or carers.
Following discharge the junior doctor from the dischar-
ging medical team will be asked to complete a question-
naire to determine their judgement of the likelihood of
the patient experiencing MRH during the 8 week follow
up period. This section of the data collection form is
based on the National Patient Safety Agency (NPSA) Risk
Model Matrix where the likelihood of an event is rated
against the consequence [19]. The junior doctor will be
asked to predict the likelihood that the patient will be re-
admitted or access healthcare in the community due to
MRH in the ensuing 8 weeks post discharge (doubtful,
Fig. 1 Data collection flow chart. This flow chart outlines the process that the research nurses at respective sites will use to recruit patients for
the study from inpatient hosptial wards and the biopsychosocial data that was collected at baseline. The flow chart further outlines the three
types of patient follow-up that will be conducted in order to determine medication harm eight weeks following hospital discharge. This includes
review of any hospital re-admissions, a patient interview and review of General Practice records. These three sources of information will finally be
triangulated to determine overall if medication harm has occurred
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possible, probable, definite) and will be asked to rate their
confidence in this decision (a 6 point scale from ‘little or
no confidence’ to ‘virtually certain’).
Follow up
Eight weeks post discharge the research pharmacist at
each site will conduct a telephone interview with the
patient and/or carer using a standard questionnaire to
determine whether the patient has experienced MRH.
The patient/carer will be asked about their health ser-
vice utilization over the preceding 8 weeks (GP visit,
Out of Hours visit, hospital attendance/re-admission).
The patient’s adherence to their medications will also
be determined, and the patient will be asked whether
they have recognized any unwanted reactions or ef-
fects from their medications. The research phar-
macists will also review the GP patient records to
determine whether the patient had experienced MRH
and had, as a consequence, required additional health
care support.
Any re-admitted patient will continue to be followed
up for the eight week period after the original discharge
date and telephone follow-up and GP record data will be
collected as standard.
Patients who completed their eight week follow-up
period and wish to participate in the study again, following
a repeat admission, will be allowed re-enter the study.
They will be allocated a new UPIN which will be linked to
their first UPIN to allow for sub-analysis of patients who
are re-admitted to hospital.
Please see Fig. 2 for a flow-chart detailing this follow-
up process.
Decision making
– Key information required to support the research
pharmacists (and consultant physicians where
relevant) in determining the likelihood that the
patient has experienced MRH include current
medications and any recent changes to medication,
assessment of patient’s adherence, history of
presenting complaint and ADR profile of the
prescribed medicines, relevant co-morbidities, and
appropriate clinical observations and investigations.
MRH will be categorised as doubtful, possible,
probable, or definite.
– Where an ADR is suspected the Naranjo algorithm
will be utilised to support the causality assessment
[20]. The Naranjo algorithm rates the causality
conservatively as many of questions are not relevant
e.g. did the same reaction occur when placebo was
administered? Therefore it will be used as a guide to
ensure temporal association, previous reports of the
reaction and other possible causes are all considered
when determining MRH due to an ADR.
– For an assessment of patient adherence to their
medications, the Morisky scale [21] will be used.
– Where MRH is unclear, or if the admitting
consultant and pharmacist cannot agree for
re-admissions, cases are presented by the research
pharmacist to the local End Point Committee (EPC)
for further discussion and decision making.
– If a patient was re-admitted during the 8-week
follow up period, data pertaining to that re-admission
will be collected. The likelihood that the re-admission
was due to MRH will be assessed by the research
pharmacist and the admitting consultant physician
using a standardized approach which
incorporates the outcome from the Naranjo
algorithm and the Morisky scale (as outlined above)
(Table 1).
Triangulation of outcomes
The outcomes recorded for each follow up stage (i.e.
Patient telephone interview, GP records review, and
re-admission where applicable) will be reviewed to deter-
mine the final outcome.
For each event the following will be recorded with the
benefit of the complete follow-up by either the lead re-
search pharmacist (JS), research fellow (NP), Professor
of Clinical Pharmacy & Therapeutics (GD) or the Chief
Investigator (KA):
Table 1 The process by which Medication-related harm outcomes are recorded
Question Options
- 1. Do you think this patient has suffered medication related harm? ○ Definite, Probable, Possible, Doubtful
- 2. How confident are you in this judgement? ○ little or no confidence, slight to moderate confidence, <50 %
confidence but a close call, >50 % confidence but a close call,
strong confidence, virtually certain
- 3. If the patient has suffered medication related harm, what was the main cause? ○ ADR, non-adherence, other, unable to determine
- What medications were implicated? Free text entered by research pharmacist
- What was the clinical event of the MRH? Free text entered by research pharmacist
- 4. If the patient has suffered medication related harm, was it preventable? ○ Definitely, possibly, not preventable, not able to determine
5. If the patient has suffered medication related harm, what was the severity? ○ Fatal, life threatening, serious, significant
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1. Has the patient suffered an MRH? Definite;
Probable; Possible; Doubtful
2. Was the MRP preventable? Definite; Possible; Not
preventable
3. What was the severity? Fatal; Life threatening;
Serious (hospitalisation); Serious (A&E); Serious
(Community Care); Serious (Self-management);
Significant
4. What was the main cause? ADR; Non-adherence;
both
5. What was the event?
6. What was the drug(s)?
The total number of events and the healthcare uti-
lization (re-admission, A&E attendance, access to out of
hours services, GP or pharmacist) due to MRH will be
recorded.
Withdrawal arrangements
Any patient who wishes to withdraw from the study is
free to do so at any point without giving any reason.
Loss to follow up
Every effort will be made by the research pharmacist to
trace participants lost to follow up. Hospital database,
GP records, and contact with any named next of kin will
be undertaken to determine whether the patient is still
alive, their state of health at the follow up point, and if
there are any new contact details.
End of study
The study will end when the final participant has com-
pleted the 8- weeks follow up.
Fig. 2 Clinical decision making flow chart. This flow chart provides a simple outline of the method which will be employed to perform an intial
assessment at follow-up of whether medication harm has occurred based on patient interview, hospital re-admission and General Practice
records. This will be followed by a final assessment of potential medication harm events, classified by likelihood, cause, severity and preventability
of the event. The binary outcome of this assessment to determine the occurrence (or not) of medication harm will inform the logistic regression
and risk prediction model development. The model will be internally validated and its ability to predict medicaiton harm will be compared to the
ability of discharging clinicians to predict medication harm at the point of hospital discharge
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Reporting of adverse events
Adverse medication-related events will be discussed
by the local EPC as appropriate and the patient’s ad-
mitting physician or patient’s GP will be subsequently
notified.
Sample size
The sample size calculation was determined to achieve a
sensitivity of 80 % with a 95 % confidence interval width
of 5 % and based on a medication related problem preva-
lence rate of 30 %. The nomogram designed by Carley
et al. [22], based on the work of Buderer [23], was used to
determine the sample size of 1500 patients. A maximum
of 50 % of the total study population may be recruited
from one site to reduce the risk of an unrepresentative
study population.
Statistical analysis
Data collected for the potential risk variables will undergo
univariate analysis to identify the variables significantly as-
sociated with binary outcome of MRH. All variables, sig-
nificant and non-significant, will be reviewed by the
expert panel for clinical relevance and consistency with
the literature. This will be conducted without prior know-
ledge of the statistical relationships of the data to avoid
introducing observer bias. It is recognised that variables
deemed non-significant upon univariate analysis should
not be removed automatically; rather their significance
should be reviewed by experts in the field, especially if the
data set is small or the prevalence is rare [24]. Significant
variables prevalent in less than 5 % of the study population
will be reviewed and potentially rejected if they are
not considered to be representative of the population.
Correlation between pre-determined variables with
likely interaction e.g. number of co-morbidities and
number of medicines will be assessed. The dichotomi-
sation of data, that is categorising continuous data
into two groups, will be avoided where possible [25].
The variables will undergo multivariable logistic re-
gression analysis and be eliminated or retained in the
model as indicated by a combination of clinical and
statistical significance.
Internal validation of the RPM using bootstrapping
will follow this.
Descriptive statistics will be applied to describe popu-
lation characteristics, healthcare utilisation and to iden-
tify any significant differences between those who
experienced MRH and those who did not. Odds ratios
will be calculated to determine the odds of a specific
medication group being associated with the need for pa-
tients to access unplanned support. Multivariable regres-
sion analysis will be applied to candidate variables to
identify the variables which, when combined, produce the
optimal RPM sensitivity and specificity. Model calibration
and discrimination will be calculated using appropri-
ate tests e.g. Hosmer-Lemeshow and Area Under the
Receiver Operating Characteristic (AUROC) curve [25].
A comparison of the predictive power of the model to the
doctors’ routine judgement will be conducted using ap-
propriate statistical techniques.
Data protection
Participant identification, data archiving, and, storage
All patients will be given a unique study number to pre-
serve confidentiality. This number will be entered into
an appropriate database and will only be traceable to an
individual patient by accessing the study form for the pa-
tient from a secure location at the Research and Devel-
opment Department at each study centre. All electronic
data will be password protected and only direct mem-
bers of the research team will have access to the full set
of electronic data generated within the study. Hard cop-
ies of all data collection forms will be stored at respect-
ive study sites for a maximum of 3 years after the study
has ended.
Ethical considerations
If during the data collection a concern is raised by the
research nurse or the pharmacist, the issue will be
discussed with the local Principal Investigator (PI), and
advice will be given to notify the patient’s GP and their
clinical teams.
Protocol compliance and deviation/violation
Notification of violation to sponsor.
Discussion
The impact of MRH in the community, and related inci-
dence of hospital admission has significant implications
for the health and quality of life of elderly people, as well
as the economic burden of avoidable primary and sec-
ondary healthcare service utilisation. Currently there is
no standardized method for identifying older people at
high risk of MRH upon discharge and thus there is no
systematic approach to guide appropriate monitoring
and intervention as needed in the community. Existing
RPMs in the context of ADR in older people that have
been developed for use within the hospital setting, and
have shown at best a moderate performance (AUROC
0.623 to 0.73) and only two models have been externally
validated [8, 9]. Therefore these prediction models are
not in widespread clinical application. The aim of this
study is to develop a clinically valuable and practical
RPM that can identify elderly people at high risk of
MRH following discharge from hospital.
It is hoped that the RPM developed through this study
will alert discharging doctors of patients at high risk for
whom an early medication review, follow-up and/or
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adjustment of discharge medications may be indicated.
A wide range of social factors (e.g. Activities of Daily
Living, Accommodation status) and measurements for
patient frailty (e.g. handgrip strength) are being mea-
sured in patients recruited for this study, which might
support a model of higher predictive value than other
tools developed in the context of MRH. Frailty has not
been previously been explored as potentially important
variable within a RPM for medication problems. Frailty
is a common geriatric syndrome that embodies a decline
in health and function associated with ageing. It is char-
acterized by a loss of functional homeostasis such that a
minor insult can result in catastrophic consequences for
the individual.
A further special and key feature of this study is
the comparison of the RPM that will be developed
with routine risk prediction by junior doctors upon
discharge of older people. This will help to determine
whether the RPM developed is superior to current
best practice.
It is acknowledged that asking the junior doctors to
prospectively review patients’ risk in this way could
affect their future behavior as described by the ‘Haw-
thorne Effect’. However, any learning effect is likely to
be limited by the frequent rotation of junior doctors.
Should this, however, influence the outcome of the study
in such a way that raises awareness of high risk patients
and results in a safer clinical judgment then this, in
itself, would be a positive outcome.
Study progress
Stage I of the study is complete, and we encourage readers
to refer to the Stevenson et al. [26] systematic review of
the existing RPMs to predict ADR in elderly people.
Stage II of the study is currently ongoing.
Additional file
Additional file 1: Table S2. Candidate Predictor Variables.
(DOCX 59 kb)
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